First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria

View source ↗

Summary

EMA recommends marketing authorization for Voydeya, the first oral treatment for Paroxysmal nocturnal haemoglobinuria patients with residual haemolytic anaemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Haemoglobinuria

Drugs mentioned

• VOYDEYA (DANICOPAN)

Snippet

EMA has recommended granting a marketing authorisation in the European Union (EU) for Voydeya, the first oral treatment for patients with paroxysmal nocturnal haemoglobinuria (PNH) who continue to have haemolytic anaemia (low levels of red blood cells) despite treatment with a C5 complement inhibitor (eculizumab or ravulizumab).